Izrael -
hebrejščina -
Ministry of Health
סטרון 1 מג
padagis israel agencies ltd, israel - granisetron as hydrochloride - טבליה - granisetron as hydrochloride 1 mg - granisetron - granisetron - prevention of nausea and vomiting induced by cytostatic therapy.
Izrael -
hebrejščina -
Ministry of Health
גרניסטרון טבע
teva pharmaceutical indust.ltd - granisetron as hydrochloride 3 mg / 3 ml - solution for infusion - granisetron - for the prevention and control of nausea and vomiting induced by cytostatic therapy (chemotherapy and radiotherapy).
Izrael -
hebrejščina -
Ministry of Health
פאלוקסי זריקות
rafa laboratories ltd - palonosetron as hydrochloride - תמיסה להזרקה - palonosetron as hydrochloride 0.25 mg/vial - palonosetron - palonosetron - prevention of chemotherapy - induced nausea and vomiting (cinv).
Izrael -
hebrejščina -
Ministry of Health
פאלוקסי זריקות
rafa laboratories ltd - palonosetron as hydrochloride - תמיסה להזרקה - palonosetron as hydrochloride 0.25 mg/vial - palonosetron - palonosetron - prevention of chemotherapy - induced nausea and vomiting (cinv).
Izrael -
hebrejščina -
Ministry of Health
פלונוסטרון טבע ® 0.25 מ"ג/5 מ"ל
teva pharmaceutical indust.ltd - palonosetron as hydrochloride 0.05 mg / 1 ml - solution for injection - palonosetron - prevention of chemotherapy - induced nausea and vomiting (cinv).
Izrael -
hebrejščina -
Ministry of Health
אימנד 80 מג קפסולות
merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
Izrael -
hebrejščina -
Ministry of Health
אימנד 80 מג קפסולות
merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
Izrael -
hebrejščina -
Ministry of Health
אימנד 80 מג קפסולות
merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
Izrael -
hebrejščina -
Ministry of Health
אימנד 125 מג קפסולות
merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
Izrael -
hebrejščina -
Ministry of Health
אימנד 125 מג קפסולות
merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.